Seagen Inc.
https://www.seagen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Seagen Inc.
Multiple Chinese Firms Expand Global Phase III Trials To Japan
The efforts add up to a new trend after Chinese pharma firms embarked on a quest to launch pivotal Phase II or III trials worldwide, especially in the US and Europe, over the past decade. Meanwhile, BeiGene, Hengrui and others are advancing late-stage programs in the US.
Market Access Strategies: Nudging Negotiations Along
Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?
Big Pharma On Steady Footing Heading Into Second Half
Large cap pharmaceutical manufacturers reassured investors that revenues are poised to grow in 2024. Now they need to deliver.
Five Recent Deals Show ADCs Aren’t Cooling Off For Summer
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alpine Biosciences
- Biomira
- Oncothyreon, Inc.
- Cascadian Therapeutics, Inc.
- Seattle Genetics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice